On November 2nd 2021, Bellamoon (Xiamen) Medical Technology Co., Ltd. released its annual report. From the perspective of operating income in 2021,We see a steady growth in performance.

Bellamoon adheres to the dual cycle of domestic and international markets and promotes mutual development.

The domestic market will continue to adhere to the hospital market as the company's main track, and the business model that combines direct sales of head hospitals with the sinking market, so as to achieve a healthy and efficient operation of the domestic market. At present, Bellamoon has covered more than 500 medical institutions across the country.

The overseas market of Bellamoon (Xiamen) Medical Technology Co., Ltd. currently covers 68 countries and cooperates with more than 100 international distributors. In 2021, its international business will achieve operating income of 109 million yuan. Catalyzed by the epidemic, overseas high-end hospital customers have made breakthroughs. The products sold by Bellamoon have generally responded well. There has been no return or dissatisfaction with the products sold internationally, laying a good foundation for the company's future international expansion.

We always stick to our original goal. Bellamoon will continue to impress customers with quality and design, and will continue to focus on providing customized services and offering solutions for the medical care industry.